Dr Ibrahim Aldoss speaks to ecancer about the outcomes of the pivotal augment-101 phase 2 study, focusing on the effectiveness and safety of revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukaemia.

Revumenib, an inhibitor targeting menin-KMT2A interactions, exhibited promising efficacy and safety during a preliminary phase 1 study involving R/R KMT2Ar and nucleophosmin 1-mutated (NPM1m) acute leukaemias.

This phase 2 study aimed to present key findings regarding the efficacy and safety of revumenib in the treatment of patients with R/R KMT2Ar acute leukaemia.

The results indicated that revumenib yielded clinically significant outcomes in a heavily treated KMT2Ar population, showcasing a high overall response rate, minimal residual disease negativity, and subsequent successful haematopoietic stem cell transplant.